



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Smith & Nephew plc  
(Registrant)

Date: November 27, 2002

By: /s/ Paul Chambers  
-----  
Paul Chambers  
Company Secretary

2

25 November 2002

Completion of Dermagraft Acquisition

Smith & Nephew, the global advanced medical devices company, announces that it has completed the \$12 million acquisition of the Dermagraft(R) and TransCyte(R) joint venture from Advanced Tissue Sciences, Inc.

Enquiries:

Christopher O'Donnell, Chief Executive  
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

Peter Hooley, Finance Director  
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

Angie Craig, Corporate Affairs Director  
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

David Yates/Jonathan Birt  
Financial Dynamics

Tel: +44 (0) 20 7831 3113

25 November 2002

Edgar Filing: SMITH & NEPHEW PLC - Form 6-K

The Secretary  
London Stock Exchange  
RNS  
Old Broad Street  
London  
EC2N 1HP

Dear Sirs,

Dealing by Director in Ordinary shares of Smith & Nephew plc

We have been informed today that Dudley Eustace, a director of Smith & Nephew plc, has acquired 195 Ordinary shares of the Company at 383.23 pence each on 22 November 2002, through the re-investment of the final dividend paid on 15 November 2002. Mr. Eustace now has a beneficial interest in 49,679 Ordinary shares being 0.0054% of the issued share capital of the Company.

Yours faithfully,

J.V. Sutton  
Assistant Company Secretary